Nanogen s NanoChip 400 Menu Could Grow as Fisher Buys Stake in Shop and Acquires Test Maker Athena | GenomeWeb

The future possibilities for Nanogen's molecular diagnostics business broadened last week when Fisher Scientific spent $15 million to buy a 9-percent stake in the San Diego-based company.

The purchase, which makes Fisher one of Nanogen's lead investors, coincided with Fisher's $283-million acquisition of Athena Diagnostics and a plan by Fisher and Nanogen to develop and sell Athena's tests. Athena, based in Worcester, Mass., makes immunohistochemical and molecular diagnostics for neurological, nephrologic, and endocrine diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.